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M A J O R A R T I C L E
Immunological Characterization and Neutralizing Ability
of Monoclonal Antibodies Directed Against Botulinum
Neurotoxin Type H
Yongfeng Fan,1 Jason R. Barash,2 Jianlong Lou,1 Fraser Conrad,1 James D. Marks,1 and Stephen S. Arnon2
1Department of Anesthesia, University of California San Francisco, San Francisco General Hospital, and 2Infant Botulism Treatment and Prevention Program, Division of Communicable Disease Control,
Center for Infectious Diseases, California Department of Public Health, Richmond
Background. Only Clostridium botulinum strain IBCA10-7060 produces the recently described novel botulinum neurotoxin
type H (BoNT/H). BoNT/H (N-terminal two-thirds most homologous to BoNT/F and C-terminal one-third most homologous to
BoNT/A) requires antitoxin to toxin ratios ≥1190:1 for neutralization by existing antitoxins. Hence, more potent and safer antitoxins
against BoNT/H are needed.
Methods. We therefore evaluated our existing monoclonal antibodies (mAbs) to BoNT/A and BoNT/F for BoNT/H binding, cre-
ated yeast-displayed mutants to select for higher-affinity-binding mAbs by using flow cytometry, and evaluated the mAbs’ ability to
neutralize BoNT/H in the standard mouse bioassay.
Results. Anti-BoNT/A HCC-binding mAbs RAZ1 and CR2 bound BoNT/H with high affinity. However, only 1 of 6 BoNT/F mAbs
(4E17.2A) bound BoNT/H but with an affinity >800-fold lower (equilibrium dissociation binding constant [KD] = 7.56 × 10
−8 M) than
its BoNT/F affinity (KD = 9.1 × 10
−11 M), indicating that the N-terminal two-thirds of BoNT/H is immunologically unique. The affinity
of 4E17.2A for BoNT/H was increased >500-fold to KD = 1.48 × 10
−10 M (mAb 4E17.2D). A combination of mAbs RAZ1, CR2, and
4E17.2D completely protected mice challenged with 280 mouse median lethal doses of BoNT/H at a mAb dose as low as 5 µg of total
antibody.
Conclusions. This 3-mAb combination potently neutralized BoNT/H and represents a potential human antitoxin that could be
developed for the prevention and treatment of type H botulism.
Keywords. monoclonal antibodies; botulinum toxin; botulism; Clostridium botulinum; botulinum neurotoxin type H;
bioterrorism; select agents.
Botulinum neurotoxin (BoNT) is the most poisonous substance
known [1] and has 3 functional domains [2]: a binding domain
(HC), a translocation domain (HN), and a catalytic domain
(LC). The HC binds receptors on the presynaptic membrane
[3–6], leading to BoNT endocytosis. After endocytosis, the HN
forms a channel across the endosomal membrane enabling de-
livery of the LC into the cytoplasm [7–9]. The LC is a zinc en-
dopeptidase that cleaves SNARE proteins, thereby blocking
synaptic vesicle fusion and acetylcholine release [10]. Serotypes
are defined immunologically in the standard mouse bioassay
and differentiated from each other by the inability of polyclonal
immunoglobulin G (IgG) antibodies that neutralize one sero-
type to neutralize the other serotypes [11–14].By this definition,
BoNT exists as 8 different serotypes, A–H [15–18]. Toxin sero-
types A, B, E, and F are further subdivided into subtypes or ge-
netic variants (eg, A1–8 and F1–7), based on immunologic and
sequence differences [19].
BoNT causes botulism in humans, is a widely used therapeutic
[20], and is also a Tier 1 (mass casualty capable) potential bio-
weapon [21, 22]. For these reasons, antitoxins neutralizing all
BoNT serotypes are needed [23]. A heptavalent (targeting sero-
types A–G) equine botulism antitoxin (BAT) produced from im-
munized horses is licensed in the United States for the treatment
of botulism [24].As a foreign protein, BAT is immunogenic, and
hypersensitivity reactions, including serum sickness and asystole,
have been reported [24].Botulism Antitoxin Heptavalent (A,B,C,
D,E,F,G) – (Equine) (BAT) is an immunoglobulin F(ab′)2 whose
7 serotype-specific components have short serum half-lives (7.5–
34.2 hours), which preclude its effective use for prophylaxis and
which may predispose to relapse of botulism after treatment [25].
As an alternative, highly potent human monoclonal antibody
(mAb)–based antitoxins composed of 3 mAbs that bind non-
overlapping epitopes [26] are being developed, with the most ad-
vanced having completed phase 1 human testing [27].
BoNT/H is produced by bivalent C. botulinum strain
IBCA10-7060 that also produces BoNT/B2 [15, 16]. Compared
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with the other 7 BoNT serotypes, BoNT/H has an N-terminal
two-thirds that is most homologous to BoNT/F and a C-termi-
nal one-third that is most homologous to BoNT/A [16]. In its
initial description, BoNT/H was not neutralized by existing
polyclonal antitoxins, which included a US Army–supplied
equine polyclonal heptavalent (targeting serotypes A–G) F(ab′)2
botulinum antitoxin at anti-A and anti-F antitoxin to toxin po-
tency ratios as high as 595:1 [15]. Neutralization only occurred
at an anti-A antitoxin ratio of 1190:1 [15]. In more recent work,
BoNT/H was neutralized by research antitoxins at ratios ranging
from 20:1 to 200:1; for neutralization, using the therapeutic
licensed BAT, a ratio of >500:1 was required [18]. We therefore
evaluated our existing mAbs to BoNT/A and BoNT/F for
BoNT/H binding, evolved one of these mAbs for higher-affinity
BoNT/H binding, and thereby created a 3-mAb combination that
potently neutralizes BoNT/H.
METHODS
Bacterial Strain and Production of BoNT/H
C. botulinum type Bh strain IBCA10-7060 culture filtrate was
prepared, sterilized, and titrated by the mouse bioassay as pre-
viously described [15]. Culture filtrates were concentrated ap-
proximately 5-fold, using Amicon concentrators (Millipore,
Bedford, Massachusetts), and the resultant concentrations
(50% mouse lethal doses [MLD50] per milliliter) of BoNT/B2
and BoNT/H were determined (Supplementary Materials).
Mouse Bioassay Neutralization Studies With Equine Polyclonal
Antitoxins
Mouse bioassay neutralization studies were performed using
sterile culture filtrate and monovalent polyclonal equine anti-
toxins A, B, and F (Centers for Disease Control and Prevention,
Atlanta, Georgia) under institutional animal care and use com-
mittee–approved protocols, as previously described [15].
Mouse Bioassay Neutralization Studies With Monoclonal Antibodies
Mixtures of either 2 or 3 monoclonal antibodies in equimolar
amounts were prepared to a final protein concentration of 1 mg/
mL in phosphate-buffered saline (PBS). mAb mixtures were seri-
ally diluted with gel phosphate diluent, and 0.1 ml of these mix-
tures were combined with 0.5 mL of culture filtrate, incubated
at room temperature for 30 minutes, and then injected intraperi-
toneally, as is done in the standard mouse bioassay with equine
monovalent polyclonal antitoxins (Supplementary Materials). In
these studies, BoNT/B activity in culture filtrate was neutralized
by using either polyclonal anti-B antitoxin or a combination of
3 mAbs known to bind to and potently neutralize BoNT/B2 [28].
mAb Generation, Production, Purification, and Characterization
All immunoglobulin G (IgG) antibodies were produced recom-
binantly from stable Chinese hamster ovary (CHO) cell lines by
cloning the VH and Vk genes of scFv as previously described
[26, 29]. All mAbs were expressed with human γ1/k constant
domains and purified on protein G (Pharmacia). IgG purity
was assessed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and the concentration was determined by mea-
suring the absorbance at 280 nm.
Screening of mAbs for Binding to BoNT/H by Enzyme-Linked
Immunosorbent Assay (ELISA)
Meso Scale Diagnostic (MSD) 96-well plates were coated with a
BoNT-specific IgG (as described below) at a final concentration
of 4 µg/mL, 30 µL/well, and incubated overnight at 4°C. After
blockingwith2%milkpowder inPBS for30minutes, 1:1PBS-dilut-
ed culturefiltrate samples (pH7.4)were added to eachwell. Binding
was detected by adding an equimolar mixture of SULFO-TAG-
labeledmAbs CR2 and RAZ1. Plates were read in aMSD SECTOR
Imager 2400 instrument.
Measurement of BoNT/H and BoNT/B2 Concentrations in Culture Filtrate
by ELISA
The concentrations of BoNT/H and BoNT/B2 in culture filtrate
were determined from standard curves as previously described
[30]. For measurement of the BoNT/B2 concentration, 2B18.3
IgG was used for capture, and SULFO-TAG-labeled 1B10.1 IgG
was used for detection. For quantification of the BoNT/H concen-
tration, 6F5.1 IgG was used for capture, and SULFO-TAG-labeled
RAZ1 was used for detection. Pure BoNT/A1 (for BoNT/H mea-
surements) and BoNT/B1 (Metabiologics; for BoNT/B2 measure-
ments) were used to construct standard curves. Culture filtrate or
BoNT/B1 standard wasmeasured in triplicate, using 3 wells on the
same plate. Plates were coated with either 6F5.1 or 2B18.3 IgG at a
final concentration of 4 µg/mL, 30 µL/well, and incubated over-
night at 4°C. Serially diluted culture filtrate samples or BoNT stan-
dards were added to each well, incubated for 1 hour, and washed,
and SULFO-TAG detection mAb was added. Plates were read in a
SECTOR Imager 2400 instrument.
Measurement of BoNT/H and BoNT/B2 Concentrations by Flow
Fluorimetry
The concentrations of BoNT/H and BoNT/B2 in culture filtrate
were measured with a KinExA 3200 instrument (Sapidyne) as
previously described [29, 31], using mAbs RAZ1 and 1B10.1, re-
spectively. Culture filtrate containing BoNT/H and BoNT/B2 was
studied at a concentration estimated to be >10-fold above the
value of the equilibrium dissociation binding constant [KD] of
the mAb for its target toxin to generate a concentration-controlled
curve for greater accuracy in measuring BoNT concentrations.
mAb-containing solutions were serially diluted 2-fold 13 times
in a constant concentration of culture filtrate, from >10-fold
above to <0.01-fold below the estimated BoNT/H or BoNT/B2
concentrations, to capture a complete binding curve. After equi-
librium was achieved, samples were passed over a flow cell packed
with Sepharose 4 Fast Flow beads (GEHealthcare) covalently cou-
pled with the measuring mAb. An Alexa-647-labeled mAb bind-
ing a nonoverlapping BoNT epitope (4E17.2A for BoNT/H, B6.1
for BoNT B2) was then passed over the flow cell, producing a sig-
nal proportional to the free BoNT in each sample. An analysis
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curve yielding values forKD and the binding concentrations of the
BoNTs was generated using KinExA Pro software (version 4.0.12)
and a 1:1 reverse-binding model.
Measurement of Antibody-Binding Affinity and Kinetics by Flow
Fluorimetry
The affinity (measured by the KD) for BoNT/A1, BoNT/B2
(kind gift of Eric Johnson), BoNT/F1, BoNT/F5 (kind gift of
Susan Maslanka), and BoNT/H was measured in a KinExA
3200 instrument as described above and previously [29, 32],
using 1:2 serial dilutions of 13 samples of mAb in a constant
concentration of pure BoNT/A1 (Metabiologics), pure BoNT/
B2, or culture filtrate containing BoNT/H at a concentration
of ≤10-fold above the estimated KD of the interaction, to ensure
a KD-controlled analysis curve. The association rate constant
(kon) was measured using either pure BoNT or culture filtrate
by passing 0.5-mL volumes over a fresh BoNT-binding bead
pack as the mixture came to equilibrium, at intervals of approx-
imately 700 seconds. Free BoNT was detected at each interval
with Alexa-647–labeled antibody as described above. The
time-dependent exponential decrease in concentration of free
BoNT as a function of time was fitted to a standard bimolecular
rate equation, using KinExA Pro software to determine kon. koff
was calculated from the product of kon × KD.
Measurement of Yeast-Displayed scFv Affinity for BoNT/H
KD was also determined using yeast-displayed scFv and flow cy-
tometry as described previously [29, 33]. Yeasts were incubated
with 5 different concentrations of crude BoNT/H in diluted cul-
ture filtrate that ranged from 10 times above to 10 times below the
KD at 4°C for 30 minutes in florescence-activated cell-sorting
buffer with proteinase inhibitor and 20 mM ethylenediaminetet-
raacetic acid (EDTA). Binding of BoNT/H to yeast-displayed
scFv was detected after incubation with 2 µg/mL of RAZ1 IgG,
followed by incubation with 1 µg/mL of goat anti-human phyco-
erythrin and anti-SV5-647. EachKD was determined in triplicate.
RESULTS
Structural Analysis of BoNT/H
BoNT/H has an N-terminal third that is most homologous to
the hybrid subtype BoNT/F5, a unique middle third that is
most homologous to BoNT/F1, and a C-terminal third that is
most homologous to BoNT/A [16]. BoNT/H and BoNT/A1
are only 49.8% identical at the amino acid level but share
92.2% identity in their HCC and 73.1% identity in their HCN do-
mains [16] (Figure 1). BoNT/H is only 52.8% identical to
BoNT/F1, with hybrid subtype BoNT/F5 [35] having higher
identity (61.8%), especially in its LC (80.1%) [16]. To visualize
how these differences influence BoNT/A and BoNT/F antibody
binding, BoNT/H amino acid differences were modeled on the
structures of BoNT/A1 and BoNT/F1 (Figure 1). BoNT/H and
BoNT/A1 share significant surface identity in their HCC do-
mains and to a lesser extent their HCN domains (Figure 1),
suggesting that BoNT/A1 antibodies that bind these domains
could bind BoNT/H. For the remainder of BoNT/H (its LC
and HN), the surface identities with BoNT/A1 and BoNT/F1
are comparable to the low identities observed between the
BoNT/A1 and BoNT/F1 serotypes (Figure 1). These low identi-
ties made it unlikely that mAbs binding the HN or LC of BoNT/
A1 or BoNT/F1 would bind BoNT/H.
Identification of mAbs Likely to Bind BoNT/H
On the basis of structural analyses, >100 published [26, 29, 32, 36,
37] and unpublished human or murine mAbs were surveyed to
identify mAbs that might bind BoNT/H, based on the criteria
that they bound either the BoNT/A1 HC or the BoNT/F1 HN or
LC (Table 1 and Figure 2). Identified mAbs bound the BoNT se-
rotype used for immunization with high affinity (KD = 8.7 × 10
−9–
1.5 × 10−12 M). mAb 4E17.2 was cross-reactive with several BoNT
serotypes, binding multiple subtypes of BoNT/A, BoNT/B, BoNT/
E, and BoNT/F [32]. Three mAbs (3D12, CR1, and 4E17.2) had
been mapped to the specific amino acids that were energetically
important for binding [37, 38]. These amino acids in BoNT/H
were identical for 3D12 and were highly conserved for CR1 and
4E17.2, suggesting a high probability of their binding to BoNT/H.
Determination of Amounts of BoNT/B2 and BoNT/H in IBCA10-7060
Culture Filtrates
A sandwich ELISA was developed as previously described (Sup-
plementary Figure 1) [30] to measure the concentrations of each
BoNT present in culture filtrate. By ELISA, the culture filtrate
concentration of BoNT/B2 was 35.3 nM (5.3 µg/mL) and that
of BoNT/H was 11.3 nM (1.7 µg/mL). The concentrations
of BoNT/B2 (33 nM; 4.96 µg/mL) and BoNT/H (7.53 nM; 1.13
µg/mL) were also measured using flow fluorimetry in a KinExA
3200 instrument (Figure 3). Values for the 2 methods were within
7% of each other for BoNT/B2 and within 34% for BoNT/H. The
greater discrepancy for BoNT/H likely resulted from less accurate
ELISA measurements due to lack of pure BoNT/H for standard
curve construction and the binding of BoNT/B2 to the cross-
reactive 4E17.2 mAb. We repeated measurement of BoNT/B2
and BoNT/H concentrations, using the KinExA 3200 instrument,
on 4 independent culture filtrates of strain IBCA10-7060. Mean
BoNT/B2 concentrations (±SD) were 6.89 ± 3.58 µg/mL, and
mean BoNT/H concentrations (±SD) were 1.31 ± 0.93 µg/mL.
On one culture filtrate sample, mouse lethality was determined
before and after the addition of anti-B antitoxin, enabling mea-
surement of lethality due to BoNT/B2 and to BoNT/H (Supple-
mentary Table 1). The relative lethality of BoNT/B2 to that of
BoNT/H in this culture filtrate was 24-fold as previously reported
[15], with 4.4-fold due to the higher concentration of BoNT/B2
and 5.47-fold due to the higher specific activity of BoNT/B2.
Evaluation of Existing mAbs for Binding to BoNT/H
Fourteen BoNT/A and BoNT/F mAbs (Table 1) were screened
for binding to BoNT/H by ELISA, including 2 control BoNT/F
HC mAbs (6F3 and 6F4) not expected to bind to BoNT/H. For
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the BoNT/A mAbs, 3D12 and its derivative, RAZ1, gave the
strongest signals, with binding also observed for CR1, CR2
(the CR1 derivative), S25, and 4E17.2 (Figure 4). For the
BoNT/F mAbs, 6F12 gave the strongest signal, with no binding
observed for BoNT/F HC mAbs 6F3 and 6F4.
mAb affinity for BoNT/H was measured by flow fluorimetry
in a KinExA 3200 instrument [29, 32, 37]. RAZ1 bound to
BoNT/H with very high affinity (KD = 4.96 × 10
−12 M, similar
to its affinity for BoNT/A1; Table 2). CR2 bound to BoNT/H
with high affinity (KD = 5.37 × 10
−9 M), approximately 400-fold
Figure 1. Amino acid and structural identity of botulinum neurotoxin type H (BoNT/H) holotoxin and domains compared to BoNT/A and BoNT/F. The table indicates the amino
acid percentage identity between the sequence of BoNT/H holotoxin and its domains [34] and the other BoNTs indicated. The figure shows the surface amino acid differences
between BoNT/H and BoNT/A1 (A), BoNT/F1 (B ), and BoNT/F5 (C ) and the difference between BoNT/F1 and BoNT/A1 (D ). Identical amino acids are colored white, and
nonidentical amino acids are in increasing shades of red as a function of the relatedness in amino acid side chain. The models were constructed using pyMol on the X-
ray crystal structure of BoNT/A1 (3BTA; A and D ) or on a model of BoNT/F built from the X-ray crystal structure of the BoNT/F1 light chain (LC; 2A97) and the BoNT/A1
heavy chain (HC; 3BTA; B and C ).
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lower than its affinity for BoNT/A1. This finding is consistent
with observed amino acid differences in the CR2 epitope on
the BoNT/HHCC. Some of these amino acid differences are iden-
tical to those in BoNT/A2 [37], and the CR2 KD for BoNT/H is
only 10-fold lower than its KD for BoNT/A2 [37]. mAb S25
bound BoNT/H with moderate affinity (KD = 1.44 × 10
−8 M).
We also measured the affinity for BoNT/H of BoNT/A mAbs
Aa (KD = 3 × 10
−12 M) and Ab (KD = 2.14 × 10
−9 M), 2 of the 3
mAbs in XOMA 3AB [27].
Only 1 of 6 BoNT/F mAbs had measurable binding affinity
for BoNT/H. mAb 4E17.2A, a higher-affinity derivative of mAb
4E17.2, bound BoNT/H with moderate affinity (KD = 7.56 ×
10−8 M), approximately 800-fold lower than its affinity for
BoNT/F1 (KD = 9.1 × 10
−11 M; Table 2). Despite binding by
ELISA, mAbs 6F6, 6F7, 6F10, 6F11, and 6F12 did not show
binding in the KinExA assay at BoNT/H concentrations up to
500 nM, indicating that their KD must be lower than 1 µM. Sim-
ilar instances are known of ELISA-positive binding associated
with very poor affinity for antigen when the solution KD is
measured [28]. This discordance presumably results from avid
solid-phase ELISA binding that does not occur in solution.
Increasing the Affinity of 4E17.2A for BoNT/H
4E17.2A affinity for BoNT/H was increased by using yeast-dis-
played libraries of 4E17.2A scFv CDRH1, CDRH3, CDRL1, and
CDRL3 mutants selected for higher-affinity binding, using flow
cytometry after labeling with culture filtrate (Supplementary
Figure 2) [29]. It was postulated that selection for higher-affinity
BoNT/F1 binding would result in increased affinity for BoNT/
H, so additional selections were done using pure BoNT/F1 to
also avoid improving the affinity of cross-reactive 4E17.2A for
BoNT/B2, rather than BoNT/H. For selections done on
BoNT/F1, a higher-affinity mAb (4E17.2B) was identified that
had 3 mutations in CDRH1 and a 30-fold and 8.4-fold increase
in affinity for BoNT/F1 and BoNT/H, respectively (Table 2 and
Table 1. Characteristics of Monoclonal Antibodies (mAbs) Binding Botulinum Neurotoxin Type A1 (BoNT/A1) and BoNT/F1
mAb Species Immunogen Epitope
BoNT/A1
KD (×10
−9 M)
BoNT/B2
KD (×10
−9 M)
BoNT/F1
KD (×10
−9 M)
BoNT/F5
KD (×10
−9 M)
BoNT/A mAbs
3D12 Human Pentavalent toxoid HCC1 0.061 NB NB NM
RAZ1 Human Pentavalent toxoid HCC1 0.002 NB NB NM
S25 Mouse BoNT/A1 HC HCC2 1.69 NB NB NM
CR1 Humanized BoNT/A1 HC HCN1 0.002 NB NB NM
CR2 Humanized BoNT/A1 HC HCN1 0.01 NB NB NM
B4 Human BoNT/A1 HC HCN2 0.095 NB NB NM
4E17.2 Human Pentavalent toxoid HN1 0.002 >100 0.664 NM
BoNT/F mAbs
6F3 Mouse BoNT/F1 HC/holotoxin HC NB NB 2.39 NB
6F4 Mouse BoNT/F1 HC/holotoxin HC NB NB 1.17 NB
6F6 Mouse BoNT/F1 HC/holotoxin HN2 NB NB 0.049 NB
6F7 Mouse BoNT/F1 HC/holotoxin LC NB NB 0.57 NB
6F11 Mouse BoNT/F1 HC/holotoxin HN2 NB NB 0.001 11.8
6F12 Mouse BoNT/F1 HC/holotoxin HN2 NB NB 0.14 13.5
6F13 Mouse BoNT/F1 HC/holotoxin HN3 NB NB 0.33 0.13
Epitope indicates the domain bound by the mAb and is arbitrarily numbered on the basis of the overlap with the other mAbs.
Abbreviations: NB, no detectable binding; NM, not measured.
Figure 2. Monoclonal antibodies (mAbs) hypothesized to bind to botulinum neu-
rotoxin type H (BoNT/H), based on its sequence identity to the HC of BoNT/A1 and
the LC and HN of BoNT/F1. Where known, the amino acids comprising the epitope
are indicated in parentheses. Numbering is based on the numbering of BoNT/A1.
The percentage identity of each domain with BoNT/F1 or BoNT/A1 is indicated.
The terms “LC” (“light chain”; molecular weight, 50 000 Da) and “HC” (“heavy
chain”; molecular weight, 100 000 Da) are historical and refer to the relative molecular
weights of the 2 polypeptide chains of BoNT after reduction of the disulfide bond.
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Supplementary Figure 2). For selections done on BoNT/H, mu-
tations were identified in CDRH3, L1, and L2 that each
increased the affinity of yeast-displayed scFv 3–4-fold for
BoNT/H. Mutations in these CDRs were combined into a single
mAb (4E17.2C), which had a 59-fold higher affinity for BoNT/
H. The affinity of 4E17.2C was further increased 8.6-fold by
randomly introducing mutations into the 4E17.2C scFv gene
and selecting for higher-affinity BoNT/H binding, yielding
mAb 4E17.2D (KD = 1.48 × 10
−10 M) with a >500-fold affinity
for BoNT/H. During the affinity maturation process, the affinity
of 4E17-based mAbs for BoNT/B2 decreased 14-fold to
5.12 × 10−7 M (Table 2).
Neutralization of BoNT/H in Mice by mAb Combinations
All mice receiving as little as 8.25 µg of the mAb pair RAZ1 and
CR2 survived challenge with 28 MLD50 of BoNT/H but had
mild botulism symptoms (Table 3). Addition of a low-affinity
third mAb (4E17.2B) showed equivalent protection. Replace-
ment of 4E17.2B with the higher-affinity 4E17.2C resulted in
5 of 8 mice surviving a 72.5 LD50 challenge. Combining
RAZ1 and CR2 with the highest-affinity 4E17.2D protected
all mice challenged with 280 LD50 of BoNT/H at a mAb dose
as low as 5 µg total antibody (Table 3). No mice survived at a
2.5 µg mAb dose, resulting in an ED50 (the dose at which
50% of mice survive) estimated to be 3.75 µg. A combination
Figure 3. Botulinum neurotoxin type B2 (BoNT/B2) and BoNT/H concentrations in culture supernatants, measured by KinExA. Monoclonal antibody (mAb) binding curves and
BoNT concentration and percentage residual error for the BoNT concentration calculated from the binding curves for BoNT/B2 (top panel) and BoNT/H (bottom panel).
Figure 4. Enzyme-linked immunosorbent assay (ELISA) of monoclonal antibody
(mAb) binding to botulinum neurotoxin type H (BoNT/H) in culture supernatant.
ELISA signals denote the binding of the indicated BoNT/A and BoNT/F mAbs to
BoNT/H in culture supernatant. The concentration of BoNT/H was estimated to
be approximately 1 nM. The indicated mAb was coated on an ELISA plate, with bind-
ing detected using an equimolar mixture of mAbs CR2 and RAZ1.
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of 1 IU of polyclonal anti-BoNT/A, 1 IU of polyclonal anti-
BoNT/B, and 1 IU of polyclonal anti-BoNT/F did not protect
mice challenged with 280 LD50 of BoNT/H (Table 3).
DISCUSSION
The results demonstrate the value of having developed well-
characterized mAb binding epitopes that are conserved between
Table 2. Affinities and Binding Kinetics of Monoclonal Antibodies (mAbs) Binding Botulinum Neurotoxin Type H (BoNT/H)
mAb
BoNT/H
kon (/Ms) koff (/s)
BoNT/F1
kon (/Ms) koff (/s)
BoNT/B2
KD (×10
−9 M) KD (×10
−9 M) KD (×10
−9 M)
S25 14.43 NM NM NB . . . . . . NB
RAZ1 0.005 4.50e + 06 2.16e− 05 NB . . . . . . NB
CR2 5.37 2.92e + 06 1.57e− 02 NB . . . . . . NB
4E17.2A/6F5.1 75.59 1.63e + 5 1.27e− 02 0.091 1.42e + 06 1.29e− 04 35.9
4E17.2B/6F5.2 9.05 6.90e + 04 6.24e− 04 0.003 1.10e + 06 3.58e− 06 93.6
4E17.2C/6F5.3 1.28 4.01e + 05 5.13e− 04 0.162 1.05e + 06 1.70e− 04 117.3
4E17.2D/6F5.4 0.148 5.67e + 05 8.24e− 05 0.015 1.63e + 06 2.41e− 05 512.3
KD and kon were measured by flow fluorimetry in a KinExA 3200 instrument, and koff was calculated as KD * kon. The affinity of 3D12 and CR1, lower affinity parental mAbs of RAZ1 and CR2,
respectively, was not measured.
Abbreviation: NB, no detectable binding.
Table 3. Protection of Mice From the Lethal Effects of Botulinum Toxin Type H (BoNT/H) by Combinations of Monoclonal Antibodies (mAbs) and Polyclonal
Antibodies (pAbs)
A. Double and triple mAb combination and BoNT/H challenge dosea
Antibody Combinations
BoNT/H
MLD50/Mouse
Dose of mAbs
per Mouse (µg)
Mouse Survival After Intraperitoneal Injection of
BoNT Culture
Filtrate Only
BoNT Culture Filtrate
Plus mAb Mixture
RAZ1, CR2 28 66 0/4 4/4a
28 33 0/4 4/4a
28 16.5 0/4 4/4a
28 8.25 0/4 4/4a
RAZ1, CR2, 4E17.2B 28 100 0/4 4/4a
28 50 NDb 4/4a
28 25 NDb 4/4a
28 12.5 NDb 4/4a
RAZ1, CR2, 4E17.2C 1160 50 0/2 0/8
290 50 0/2 1/8
72.5 50 0/2 5/8
18.1 50 0/2 8/8
B. Comparison of mAb combination to monovalent polyclonal antitoxin combinationc
Mouse Survival after Intraperitoneal injection of
BoNT/H
MLD50/Mouse
Dose of
Abs per Mouse
BoNT Culture
Filtrate Only
BoNT Culture Filtrate
Plus Antibody Mixture
RAZ1, CR2, 4E17.2D 280 100 µg total mAb 0/2 4/4
Polyclonal anti-A, B, F 280 1.0 IU of each pAb 0/2 0/4
C. Determination of mAb combination neutralizing potency by serial dilutiona
BoNT/H
MLD50/Mouse
Dose of mAb/
Mouse (µg)
Mouse Survival After Intraperitoneal Injection of
BoNT Culture
Filtrate Only
BoNT Culture
Filtrate Plus mAbs
RAZ1, CR2, 4E17.2D 280 50 0/4 4/4
280 5 0/4 4/4
280 2.5 0/4 0/4
280 1.25 0/4 0/4
a The BoNT/B in the culture filtrate was neutralized by including in the intraperitoneal injection mixture an excess of a 3-mAb combination that specifically neutralizes BoNT/B.
b The experiment was not done (ND) because the first (control) experiment demonstrated that the 28 LD50s BoNT/H in the CF was lethal for all mice tested.
c BoNT/B was neutralized by an excess of polyclonal anti-BoNT/B or mAb combination; mice were observed for 8 days. Note failure of the polyclonal anti-A immunoglobulin G (IgG) plus
polyclonal anti-F IgG combination to neutralize BoNT/H.
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subtypes of BoNT/A, /B, /C, /D, /E, and /F. Detailed knowledge
of the serotype specificity, domain bound, and in some instanc-
es, fine epitope structure allowed rapid in silico prediction and
experimental confirmation of mAbs that would bind BoNT/H.
All 3 BoNT/A mAbs binding the more homologous HCC and 1
of 2 BoNT/A mAbs binding the less homologous HCN bound to
BoNT/H with high affinity. However, only a single BoNT/F
mAb bound BoNT/H, with only an affinity 800-fold lower
than its affinity for BoNT/F. These binding and affinity differ-
ences demonstrate that the low sequence and surface identity
between the LC and HN of BoNT/H and BoNT/F translate
into immunologic uniqueness between these serotypes. mAbs
and antitoxins generated by immunization with BoNT/F
would be unlikely to bind or neutralize BoNT/H, as shown in
this work and as reported by others [15, 18].
These studies provide mAbs useful for the specific diagnosis
of type H botulism. Four mAbs binding nonoverlapping epi-
topes with high affinity were identified that could be used to de-
velop mass spectrometry–based or other assays to detect BoNT/
H in environmental samples, blood, or stool [39, 40]. A BoNT/
H-specific sandwich ELISA would require development of a
BoNT/H-specific mAb.
The humanized and human mAbs reported here may also be
developed as BoNT/H therapeutic and prophylactic antitoxins.
An equimolar combination of the human mAb RAZ1 and the
humanized mAb CR2 neutralized BoNT/H in vivo with a po-
tency of 3400 MLD50/mg (calculated using data from Table 3).
While we did not titer the 2-mAb potency in IU, this calculated
potency can be approximated into IU by dividing by 10 000
MLD50/IU [26], which yields 0.34 IU/mg. mAbs Aa and Ab, 2
of the 3 component mAbs in XOMA 3AB, also bound BoNT/H
with affinities slightly higher than the affinities of RAZ1 and
CR2. XOMA 3AB is a 3-mAb-combination pharmaceutical
product being developed to treat type A botulism that has com-
pleted human phase 1 testing without adverse safety effects [27].
Based on relative affinities, the potency of in vivo neutralization
of BoNT/H by XOMA 3AB should be at least equal to that of the
RAZ1/CR2 combination. Adding the human mAb 4E17.2D to
RAZ1 and CR2 resulted in a 3-mAb combination that potently
neutralized BoNT/H (whereas combining polyclonal anti-A plus
polyclonal anti-F antitoxins did not neutralize BoNT/H; Table 3).
As little as 5 µg of the 3-mAb combination completely neutral-
ized 280 MLD50, indicating a potency of at least 56 000 LD50/mg
(5.6 IU/mg). The increase in potency observed by adding a third
mAb is consistent with prior studies [26].
The neutralizing potencies of BAT and the 3-mAb anti-
BoNT/H combination described here may be compared. A
vial of BAT contains approximately 325 mg of antibody and a
minimum potency of 4500 IU of anti-BoNT/A [24].As reported
elsewhere, BAT is >500-fold less potent for BoNT/H than for
BoNT/A1 [18]. As a result, the potency of a vial of BAT for
BoNT/H would be 4500 IU/500, or <9 IU. This translates
into 0.028 IU/mg of BAT, >10-fold less potent than that of
the mAb pair RAZ1 plus CR2 (0.34 IU/mg) and 200-fold less
potent than the triple mAb combination RAZ1, CR2, and
4E17.2D (5.6 IU/mg).
To ensure adequate treatment, BoNT antitoxins such as BAT
are given in substantial excess of the amount of systemic BoNT
expected to be in the patient. At Cmax a single vial of BAT pro-
vides enough anti-BoNT/A antibody to neutralize 26 900
MLD50 of BoNT/A per milliliter of serum [24]. Based on the
preceding calculations, the Cmax value equates to a neutralizing
capacity of <54 MLD50/mL for BoNT/H. One human food-
borne botulism patient had a serum BoNT concentration of
32 MLD50/mL [41], with the highest foodborne botulism
serum concentration ever detected being 1800 LD50/mL of
BoNT/A [42]. Serum concentrations of BoNT that might result
from its bioterrorist use are unknown. Comparison of the esti-
mated BoNT/H neutralizing activity of BAT (<54 MLD50/mL)
with reported BoNT serum concentrations (up to 1800 LD50/
mL) indicates that, in some patients, a single vial of BAT
might be inadequate to neutralize potential BoNT/H serum
concentrations. In addition, the observed persistence of BoNT
in serum up to 25 days after exposure [42, 43] and the short half-
life of anti-BoNT/A in BAT (8.6 hours) [24] heighten the need
to anticipate relapse and to consider early BAT readministration
where possible [25]. Such considerations also highlight the need
to determine the actual potency of BAT against BoNT/H in the
physiological primate disease model and to consider developing
BoNT/H-specific antitoxins. XOMA 3AB should be studied as
an interim BoNT/H therapeutic because, on a per-milligram
basis, it should have neutralizing activity against BoNT/H
comparable to BAT, was safe in a phase 1 trial [27], and has a
significantly longer serum half-life (10.3–24.0 days for its 3-
component mAbs) than the anti-BoNT/A activity in BAT (8.6
hours) [24]. The 3 mAbs described here could be further devel-
oped into a highly potent 3-mAb combination to BoNT/H. Fi-
nally, since BoNT/H has a mosaic structure, it would be prudent
to develop mAbs specific to the immunologically unique LC
and HN of BoNT/H, as there likely exists in nature the parental
BoNT/H whose HC was replaced by a BoNT/A-like HC that
would not be neutralized by existing antitoxins.
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